Skip to main content
. Author manuscript; available in PMC: 2013 Mar 11.
Published in final edited form as: Leukemia. 2012 Oct 1;27(3):586–594. doi: 10.1038/leu.2012.276

Figure 3. Effects of MLN0128 alone or in combination with dasatinib in primary non-Ph and Ph+ B-ALL specimens.

Figure 3

(A) Anti-clonogenic effects of compounds were compared in Ph+ specimens (n=6) treated with rapamycin (Rapa), PP242 or MLN0128 alone or in the presence of 5.0 nM dasatinib (DA). Cytokine supplemented Methocult GF+H4435 cultures were scored for colonies after 12–14 days and normalized to control (vehicle-treated). Some of the data shown here were from specimens included in a broader comparison of rapamycin and PP242 published previously (9), though MLN0128 data were not included at that time. (B–C) Adult and pediatric non-Ph mixed karyotype B-ALL specimens (n=7) were cultured with the indicated compounds at 20 nM or 200 nM and colonies were scored after 14 days. (D) Co-culture of human hTERT-immortalized marrow stromal cells (MSC) with pediatric non-Ph mixed karyotype B-ALL specimens (n=7) for 24 hr, followed by 24 hr treatment of indicated inhibitors. % death was analyzed by 7-AAD dye exclusion by flow cytometry in human CD19+ cells.